| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, ... New England Journal of Medicine 369 (1), 32-42, 2013 | 2857 | 2013 |
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ... New England Journal of Medicine 370 (11), 997-1007, 2014 | 2261 | 2014 |
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies RH Advani, JJ Buggy, JP Sharman, SM Smith, TE Boyd, B Grant, ... Journal of Clinical Oncology 31 (1), 88-94, 2013 | 1449 | 2013 |
| Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia JW Friedberg, J Sharman, J Sweetenham, PB Johnston, JM Vose, ... Blood, The Journal of the American Society of Hematology 115 (13), 2578-2585, 2010 | 978 | 2010 |
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ... Blood, The Journal of the American Society of Hematology 122 (15), 2539-2549, 2013 | 878 | 2013 |
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial S O'Brien, RR Furman, SE Coutre, JP Sharman, JA Burger, KA Blum, ... The lancet oncology 15 (1), 48-58, 2014 | 730 | 2014 |
| Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... The Lancet 395 (10232), 1278-1291, 2020 | 700 | 2020 |
| Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trněný, JP Sharman, ... New England Journal of Medicine 386 (4), 351-363, 2022 | 621 | 2022 |
| Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience S O’Brien, RR Furman, S Coutre, IW Flinn, JA Burger, K Blum, J Sharman, ... Blood, The Journal of the American Society of Hematology 131 (17), 1910-1919, 2018 | 459 | 2018 |
| Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin SM Horwitz, RH Advani, NL Bartlett, ED Jacobsen, JP Sharman, ... Blood, The Journal of the American Society of Hematology 123 (20), 3095-3100, 2014 | 400 | 2014 |
| Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 M Roschewski, MS Lionakis, JP Sharman, J Roswarski, A Goy, ... Science immunology 5 (48), eabd0110, 2020 | 385 | 2020 |
| Management of adverse events associated with idelalisib treatment: expert panel opinion SE Coutré, JC Barrientos, JR Brown, S de Vos, RR Furman, MJ Keating, ... Leukemia & lymphoma 56 (10), 2779-2786, 2015 | 364 | 2015 |
| Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression ED Jacobsen, JP Sharman, Y Oki, RH Advani, JN Winter, CM Bello, ... Blood, The Journal of the American Society of Hematology 125 (9), 1394-1402, 2015 | 330 | 2015 |
| Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell … D Chiron, M Di Liberto, P Martin, X Huang, J Sharman, P Blecua, ... Cancer discovery 4 (9), 1022-1035, 2014 | 325 | 2014 |
| Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3 … AD Zelenetz, JC Barrientos, JR Brown, B Coiffier, J Delgado, M Egyed, ... The Lancet Oncology 18 (3), 297-311, 2017 | 277 | 2017 |
| Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) F Morschhauser, IW Flinn, R Advani, LH Sehn, C Diefenbach, K Kolibaba, ... The Lancet Haematology 6 (5), e254-e265, 2019 | 264 | 2019 |
| Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia JP Sharman, SE Coutre, RR Furman, BD Cheson, JM Pagel, P Hillmen, ... Journal of Clinical Oncology 37 (16), 1391-1402, 2019 | 245 | 2019 |
| An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia J Sharman, M Hawkins, K Kolibaba, M Boxer, L Klein, M Wu, J Hu, ... Blood, The Journal of the American Society of Hematology 125 (15), 2336-2343, 2015 | 207 | 2015 |
| Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, K Blum, ... Clinical Cancer Research 26 (15), 3918-3927, 2020 | 204 | 2020 |
| Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... Leukemia 36 (4), 1171-1175, 2022 | 199 | 2022 |
john C. ByrdDistinguished University Professor, The Ohio State UniversityZweryfikowany adres z osumc.edu
